The Kidney Recipient with New Diabetes

This flow traces the development of transplant-related diabetes as an interaction between HCV, metabolic vulnerability, and immunosuppression.

increasingBearing stren­gth in each eventdecreasing

Metabolic Predisposition

Metabolic Predisposition A latent risk HCV is associated with Insulin resistance and a higher prevalence of Diabetes mellitus even before transplantation. Obesity, age, ethnicity, and dialysis-related metabolic stress add further vulnerability. A risk awaiting pressure The patient may have no overt diabetes at listing, yet the metabolic system is already unstable. Transplantation will expose that instability to steroids and calcineurin inhibitors.

Posttransplant Trigger

Posttransplant Trigger Immunosuppressive force High early doses of corticosteroids and calcineurin inhibitors can reveal or intensify glucose intolerance. Tacrolimus is repeatedly associated with greater diabetes risk than cyclosporine. Viral contribution Enhanced HCV replication may add inflammatory and metabolic pressure. The new diagnosis is therefore neither purely drug-induced nor purely viral.

Cardiovascular Cost

Cardiovascular Cost More than a laboratory value New diabetes increases vascular risk in a population already vulnerable to cardiovascular disease. HCV-positive recipients consequently face an amplified mortality pathway. Preventive adjustment Immunosuppression, glucose control, nutrition, and HCV management must be coordinated. Preventing diabetes becomes part of preserving both recipient survival and graft function.

before transplantation

first months after Kidney transplantation

long-term after transplantation